The end is where we start from: withdrawal of 17-alpha hydroxyprogesterone caproate to prevent recurrent preterm birth

Am J Obstet Gynecol. 2024 Jan;230(1):1-9. doi: 10.1016/j.ajog.2023.08.031. Epub 2023 Oct 3.

Authors

David B Nelson¹, Christina L Herrera², Donald D McIntire², F Gary Cunningham²

Affiliations

¹ Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX. Electronic address: [email protected].
² Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX.

PMID: 37798189
PMCID: PMC10842149 (available on 2025-01-01)
DOI: 10.1016/j.ajog.2023.08.031

No abstract available

Publication types

Editorial

MeSH terms

17 alpha-Hydroxyprogesterone Caproate
Female
Humans
Hydroxyprogesterones / therapeutic use
Infant, Newborn
Premature Birth* / prevention & control
Progestins / therapeutic use

Substances

17 alpha-Hydroxyprogesterone Caproate
Hydroxyprogesterones
Progestins

Grants and funding